Caffeine is the most consumed psychoactive substance in the world. Its properties are valuable in sports, since it acts as an adenosine receptor antagonist, increasing the noradrenaline and dopamine release of the central nervous system, reducing perceived exertion and pain and reducing fatigue. Despite its beneficial effects, some people appear not to benefit from caffeine supplementation, with purported genetic differences considered a contributing factor. It has been hypothesized that the CYP1A2 -163C>A polymorphism is the main gene responsible for these differences, considering that the C-allele carriers are slow metabolizers and could benefit less from caffeine intake when compared to homozygous AA for this gene (fast metabolizers). However, the time-course profile of caffeine in blood, and its derivates (dimethylxanthines), and the relation with genotype have not been shown in the literature. Also, the performance differences between individuals with different genotypes are contradictory and use small sample sizes. The aim of this study is to determine whether there are changes in the time-course of blood caffeine and dimethylxanthines concentration and performance between the different genotypes for CYP1A2.
News published in Agência FAPESP Newsletter about the scholarship: